Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Technology appraisal guidance
Reference number: TA269
Published: 12 December 2012
Last updated: 01 January 2015

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix B - proposal paper presented to the Institutes Guidance Executive

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix B - proposal paper presented to the Institutes Guidance Executive

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix B - proposal paper presented to the Institutes Guidance Executive
17 November 2014
(247.65 Kb 12 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 17 November 2014